Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Haemonetics Corporation Common Stock (NY:HAE)

122.98 +0.92 (+0.75%)
Delayed Quote Updated: 2:31 PM EDT, Oct 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Haemonetics Corporation Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Where Haemonetics Stands With Analysts ↗
 
Via Benzinga
News headline image
How 2022's Biggest Healthcare Gainers Could Fare In 2023
Health care stocks were hit hard early in the pandemic but these three have made quite a comeback. This article examines where they could go in 2023 
Via MarketBeat
9 Analysts Have This to Say About Haemonetics ↗
 
Via Benzinga
News headline image
InMode Stock Shows Improved Technical Strength; Hits Key Technical Threshold ↗
The Relative Strength (RS) Rating for InMode stock moved up into a higher percentile Wednesday, as it got a lift from 64 to 78. 
Via Investor's Business Daily
News headline image
Analysts Take Bullish Stance On Haemonetics, Cites Plasma Momentum As Catalyst ↗
 
Via Benzinga
News headline image
Haemonetics: Q2 Earnings Insights ↗
Haemonetics (NYSE:HAE) reported its Q2 earnings results on Monday, November 7, 2022 at 06:00 AM. Here's what investors need to know about the announcement. Earnings Haemonetics beat estimated earnings... 
Via Benzinga
News headline image
Expert Ratings for Haemonetics ↗
Over the past 3 months, 6 analysts have published their opinion on Haemonetics (NYSE:HAE) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
Watch for Continued Gains in Shares of Haemonetics Corporation (HAE)
Via Investor Brand Network
News headline image
Where Haemonetics Stands With Analysts ↗
  Within the last quarter, Haemonetics (NYSE:HAE) has observed the following analyst ratings: 
Via Benzinga
News headline image
Haemonetics: Q1 Earnings Insights ↗
  Haemonetics (NYSE:HAE) reported its Q1 earnings results on Wednesday, August 10, 2022 at 06:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Thursday ↗
  During Thursday's session, 108 stocks hit new 52-week highs. 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For October 13, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Haemonetics Stock Near Buy Zone With EPS Due ↗
With its next earnings report scheduled for around Aug. 10, Haemonetics stock is trading about 10% shy of a 75.44 buy point. 
Via Investor's Business Daily
News headline image
Raymond James Thinks Haemonetics Growth Is 'Underappreciated' ↗
 
Via Benzinga
News headline image
Haemonetics: Q4 Earnings Insights ↗
Haemonetics (NYSE:HAE) reported its Q4 earnings results on Tuesday, May 10, 2022 at 06:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Leading Medical Stocks, Including Sensus And Shockwave, Have Grown At Least 36% This Year ↗
Biotech isn't the only place to make money in health care this year. 
Via Investor's Business Daily
News headline image
Cutera Stock Earns Relative Strength Rating Upgrade ↗
On Monday, medical aesthetic Cutera stock had its Relative Strength (RS) Rating upgraded to 90 from 80 a day earlier. 
Via Investor's Business Daily
News headline image
Important Biotech Catalysts For September 12, 2022 - End Of The Day Summary ↗
 
Via Benzinga
News headline image
Stock Market Rally Rises On Inflation Data; Nvidia, Micron, Tesla, Disney In Focus: Weekly Review ↗
The major indexes continued to advance, despite some key warnings. 
Via Investor's Business Daily
News headline image
Analyst Ratings For Haemonetics ↗
Analysts have provided the following ratings for Haemonetics (NYSE:HAE) within the last quarter: 
Via Benzinga
News headline image
Haemonetics Surges Closer To A Breakout After Squashing Quarterly Estimates, Raising Guidance ↗
The blood and plasma supplies provider also raised its sales guidance for the fiscal year. 
Via Investor's Business Daily
News headline image
InMode Stock Scores Relative Strength Rating Upgrade; Hits Key Threshold ↗
On Tuesday, InMode stock got a positive adjustment to its Relative Strength (RS) Rating, to 86 from 72 a day earlier. 
Via Investor's Business Daily
News headline image
ShockWave Medical Stock Scores Rising Price Performance With Jump To 92 RS Rating ↗
ShockWave Medical stock saw a welcome improvement to its Relative Strength (RS) Rating on Monday, with an increase from 81 to 92. 
Via Investor's Business Daily
News headline image
Morgan Stanley Maintains Equal-Weight Rating for Haemonetics: Here's What You Need To Know ↗
Morgan Stanley has decided to maintain its Equal-Weight rating of Haemonetics (NYSE:HAE) and raise its price target from $60.00 to $70.00. Shares of Haemonetics are trading up 1.46% over the last 24... 
Via Benzinga
News headline image
4 Analysts Have This to Say About Haemonetics ↗
Over the past 3 months, 4 analysts have published their opinion on Haemonetics (NYSE:HAE) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
News headline image
Needham Sees Reasonable Forecasts For Haemonetics, With Some Tailwinds ↗
Haemonetics Corporation's (NYSE: HAE) analyst day later this month may include an update on its businesses, new products, margin outlook, and financial targets for FY24-FY26. 
Via Benzinga
News headline image
ShockWave Medical Stock Shows Rising Price Performance With Jump To 91 RS Rating ↗
On Monday, ShockWave Medical stock received an upgrade to its Relative Strength (RS) Rating, from 86 to 91. 
Via Investor's Business Daily
News headline image
77 Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers 
Via Benzinga
News headline image
103 Biggest Movers From Yesterday ↗
Gainers 
Via Benzinga
News headline image
The Week Ahead In Biotech (May 8-14): Bausch Health Headlines Smid-Cap Earnings, Veru's Pre-EUA Meeting, Conference Presentations And More ↗
Biotech stocks declined yet again in the week ending May 6, dragged lower by macroeconomic concerns following the Federal Reserve's 50-basis-point rate hike. The iShares Biotechnology ETF (NASDAQ:... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.